At the forefront of addressing this challenge is Michael Gomes, a PhD candidate at the Wits Advanced Drug Delivery Platform (WADDP), who has recently been awarded the prestigious 2026 South African Medical Research Council (SAMRC) Institutional Clinician Researcher Development Programme scholarship. This grant empowers Gomes to accelerate his innovative research focused on developing nanoparticle-based drug delivery systems engineered specifically for glioblastoma treatment. His interdisciplinary work intertwines clinical insights with nanotechnology, aiming to revolutionize how chemotherapy agents reach and eradicate brain tumors.

One of the pivotal obstacles in glioblastoma therapy is the blood-brain barrier (BBB), a physiological safeguard that limits the penetration of many systemic chemotherapy agents into the brain. This barrier, while protecting neural tissue from toxins and pathogens, also inadvertently restricts drug delivery to tumor sites, rendering many conventional treatments ineffective. Addressing this, Gomes’s research explores advanced nanoscale drug carriers capable of surmounting the BBB or bypassing it altogether, ensuring a sufficient concentration of chemotherapeutic drugs directly at the tumor microenvironment.

The project systematically evaluates three distinct nanoparticle platforms: liposomes, polymer-based particles, and polydopamine nanoparticles. Liposomes—lipid bilayer vesicles—are renowned for their biocompatibility and have already been employed successfully in various drug delivery contexts due to their ability to encapsulate hydrophilic and hydrophobic compounds alike. Polymer-based nanoparticles, often synthesized from biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), offer controlled release profiles and can be functionally tailored to respond to the tumor’s biological milieu, such as pH or enzymatic activity.

The most novel aspect of Gomes’s investigation focuses on polydopamine nanoparticles. Inspired by dopamine, a neurotransmitter intrinsically present in the brain, polydopamine exhibits remarkable adhesive properties, photo- and chemo-stability, and exceptional biocompatibility. This synthetic polymer holds promise as a versatile drug carrier platform, potentially achieving enhanced cellular uptake and targeted delivery. Its inherent similarity to endogenous brain molecules may facilitate safer interactions and reduce immune responses, a critical consideration in neuro-oncological therapeutics.

Furthermore, Gomes’s research ventures beyond traditional drug administration routes by leveraging the glymphatic system—a recently elucidated cerebrospinal fluid (CSF)-mediated waste clearance pathway in the brain. Unlike systemic delivery, which requires crossing the BBB, the glymphatic route allows agents introduced directly into the CSF to diffuse through perivascular spaces and navigate towards brain tissues, including tumor sites. This paradigm shift in drug delivery could heighten tumor-targeted drug concentrations while minimizing systemic toxicity, representing a transformative approach in glioblastoma therapy.

This pioneering work exemplifies the power of integrating cutting-edge nanotechnology with an in-depth understanding of neurophysiology. By exploiting the glymphatic system, Gomes aims to surmount the inherent obstacles imposed by the BBB, tailoring drug delivery systems that mirror the brain’s natural transport mechanisms. Achieving effective chemotherapy delivery via this pathway could redefine therapeutic strategies, potentially improving survival and quality of life for glioblastoma patients globally.

Supported by the SAMRC Clinician Researcher Development Programme, the scholarship reflects a strategic investment in cultivating clinician-scientists who bridge the gap between bench and bedside. Gomes’s dual training as a medical student and researcher positions him uniquely to identify unmet clinical needs and translate laboratory discoveries into tangible therapeutic innovations. His ultimate ambition is to specialize in neurosurgery, integrating surgical expertise with research insights to develop and refine treatment modalities for brain cancer.

Under the mentorship of distinguished experts including Dr. Divesha Essa, Dr. Nnamdi Ikemefuna Okafor, Professor Dinesh Naidoo, and Professor Yahya Choonara at WADDP, Gomes’s research benefits from an environment dedicated to translational science. Essa emphasizes the indispensable role of clinician-scientists in ensuring that scientific breakthroughs pragmatically address patient care complexities. “Their clinical exposure equips them with nuanced understanding that informs the design and implementation of more effective therapies,” she notes.

The collaborative ecosystem at WADDP, combining state-of-the-art laboratory modeling, neurosurgical expertise, and advanced drug delivery platforms, epitomizes a modern approach to tackling brain tumors. This confluence permits realistic in vitro and in vivo evaluations of novel drug carriers, optimizing formulations in the context of clinical realities. As Choonara articulates, fostering early-career investigators through such scholarships is vital for sustaining innovation pipelines capable of delivering relevant, patient-centered solutions.

In essence, Michael Gomes’s research represents a beacon of hope amidst the daunting challenge posed by glioblastoma. By integrating innovative nanoparticle systems, exploiting the glymphatic pathway, and maintaining a keen focus on clinical translatability, his work aspires to elevate brain cancer therapeutics beyond current limitations. The ultimate goal is not only to prolong survival but also to enhance the quality of life for patients confronting this aggressive disease.

His pursuit underscores the critical importance of merging scientific ingenuity with clinical acumen, a synergy that promises to unlock new horizons in the fight against one of the most formidable cancers. As this research evolves, it may lay the groundwork for groundbreaking therapies capable of overcoming the biological and technical barriers that have long hindered progress in neuro-oncology.

Subject of Research: Nanoparticle-based drug delivery systems for glioblastoma, emphasizing polydopamine nanoparticles and the glymphatic system.

Article Title: Cutting-Edge Nanoparticle Therapeutics Illuminate New Pathways Against Glioblastoma

News Publication Date: Not specified (2026 implied)

Web References:

• Wits Advanced Drug Delivery Platform (WADDP) — https://www.wits.ac.za/waddp/
• Academic profiles of supervising researchers linked via Wits University

Image Credits: WADDP

Keywords: Brain cancer, Glioblastoma, Nanoparticles, Polydopamine, Drug delivery, Blood-brain barrier, Glymphatic system, Neurosurgery, Chemotherapy

Glioblastoma, renowned as the most aggressive and lethal brain tumor, presents one of the greatest therapeutic challenges in modern oncology. Characterized by rapid proliferation and invasive growth, this malignancy has consistently defied conventional treatment modalities, resulting in dismal patient prognoses. Current standard protocols—comprising maximal surgical resection followed by radiotherapy and chemotherapy—only modestly delay disease progression, with tumor recurrence typically manifesting within twelve months. In this context, a groundbreaking study emerging from the Institut de Neurociències at the Universitat Autònoma de Barcelona (UAB) heralds a potentially transformative therapeutic innovation, leveraging bioadhesive technology to selectively eradicate residual glioblastoma cells post-surgery.

The interdisciplinary research, published in the esteemed journal Advanced Science, introduces a novel class of bioadhesive patches inspired by the natural adhesive mechanisms of mussels. Mussels employ polyphenol-rich molecules to attach tenaciously to wet and uneven surfaces like submerged rocks, a strategy that researchers have ingeniously replicated to engineer patches capable of robust adhesion to moist brain tissue. This biomimicry ensures the patches remain affixed precisely to the resection cavity following tumor excision, enabling sustained and localized drug delivery that targets infiltrative cancer cells otherwise resistant to systemic therapies.

Central to the patch’s efficacy is its incorporation of catechin, a bioactive natural polyphenol commonly found in green tea, cocoa, and various fruits. Catechin functions as a potent pro-oxidative agent within the microenvironment of the patch, modulating cellular redox states to drastically elevate reactive oxygen species (ROS) levels in glioblastoma cells. The resultant oxidative stress overwhelms malignant cells’ intrinsic defenses, inducing apoptosis and achieving eradication rates approximating 90% in cultured models. Such selective cytotoxicity spares surrounding healthy brain tissue due to the localized nature of the patch’s action, addressing a critical limitation of conventional chemotherapeutic approaches that often induce systemic toxicity.

The study meticulously evaluated multiple formulations, with the catechin-enriched bioadhesive matrix demonstrating superior performance not only in standard cell culture systems but also in ex vivo experiments utilizing freshly excised porcine brain tissue. This choice of model anatomically and physiologically resembles human brain tissue, underscoring the translational potential of the technology. Adhesion strength, drug release kinetics, and biocompatibility were rigorously characterized, revealing excellent integration with cerebral surfaces and sustained catechin delivery sufficient to maintain therapeutic oxidant concentrations over extended periods.

A pivotal advantage of this localized delivery lies in its mitigation of systemic side effects traditionally associated with oral or intravenous administration of pro-oxidant agents. Catechin’s oral bioavailability and systemic metabolism have previously limited its clinical application at therapeutic doses due to off-target cytotoxicity and adverse reactions. By spatially confining catechin activity to the tumor bed, the patch markedly reduces the risk of inadvertent damage to peripheral organs, thereby improving patient safety profiles and potentially enabling higher effective dosages that maximize tumoricidal effects.

Beyond anticancer activity, these bioadhesive patches exhibit impressive antimicrobial properties, a particularly valuable attribute given the elevated risk of postoperative brain infections which complicate recovery. The polyphenol-rich adhesive matrix impedes microbial colonization and biofilm formation, facilitating a sterile healing milieu. Concurrently, excellent biocompatibility and material properties conducive to tissue regeneration were observed, promoting efficient wound healing and minimizing inflammatory responses—a common challenge in neurosurgical procedures.

From a practical perspective, the innovative fabrication process is remarkably cost-effective and straightforward, employing readily available materials and scalable techniques. This manufacturing simplicity streamlines potential clinical translation, reducing barriers related to production expenses and regulatory pathways. The capacity for mass production enhances accessibility, ensuring that effective glioblastoma treatments arising from this platform can reach a broad patient population, not limited by economic constraints or geographic location.

The collaboration spans multiple research centers in Catalonia, exemplifying a multidisciplinary approach integrating neurobiology, materials science, and oncology. These partnerships include the Institut de Neurociències-UAB (INc-UAB), the Catalan Institute of Nanoscience and Nanotechnology (ICN2), and the Bellvitge University Hospital – Catalan Institute of Oncology (ICO) – Bellvitge Biomedical Research Institute (IDIBELL). This collective expertise underpins the robustness of the study design, encompassing rigorous experimental validation and clinical insight that jointly accelerate the trajectory from bench to bedside.

Funding mechanisms supporting this research originate from prominent governmental and international bodies, including the Spanish Ministry of Science, Innovation and Universities (MICIU), the State Research Agency (AEI), and the European Regional Development Fund (ERDF – EU). Such financial backing attests to the strategic significance attributed to novel glioblastoma therapies within public health priorities, fostering an environment conducive to innovative breakthroughs that address unmet medical needs.

While current glioblastoma interventions predominantly focus on systemic chemotherapy and radiotherapy, often accompanied by deleterious side effects and limited efficacy, the mussel-inspired bioadhesive patch paradigm represents a paradigm shift. Its localized mode of action, selective targeting mechanism via oxidative stress induction, and multifunctional material properties collectively position it as a promising adjunct or alternative to existing treatment regimens. Early-stage results evince substantial tumor cell ablation capabilities, illuminating a pathway toward extending patient survival times and enhancing quality of life.

Challenges remain in the form of clinical translation, including comprehensive in vivo studies to evaluate long-term safety, optimal patch degradation kinetics, and synergistic potential with other therapeutic modalities. Furthermore, scaling from preclinical pig brain models to human neurosurgical applications will necessitate addressing anatomical variations and regulatory compliance. Nevertheless, the foundational evidence provides a compelling impetus for further investigation and rapid development.

In summary, the development of a mussel-inspired, catechin-loaded bioadhesive patch heralds a novel frontier in glioblastoma therapy, leveraging nature’s adhesive strategies to achieve localized, potent tumor cell eradication with minimized systemic toxicity. This innovation exemplifies how bioinspired engineering, combined with molecular oncology, can generate transformative solutions for some of the most intractable cancers afflicting humanity. As research progresses, this approach holds the promise of redefining therapeutic norms and offering new hope to patients confronting the daunting diagnosis of glioblastoma.

Subject of Research: Cells

Article Title: A Mussel-Inspired Bioadhesive Patch to Selectively Kill Glioblastoma Cells

News Publication Date: 27-Jan-2026

Web References: 10.1002/advs.202510658

Keywords: Neuroscience, Glioblastoma cells

Central to the challenge of treatment resistance in acute myeloid leukemia (AML) is the enigmatic role of the protein ALKBH1, as meticulously detailed by Dr. Jianjun Chen and his team. AML cells exploit a phenomenon known as codon-biased translation, enabling the preferential production of tumor-supportive proteins. ALKBH1 emerges as a key orchestrator in this process by remodeling the architecture of mitochondria, the cell’s energy hubs. This remodeling optimizes mitochondrial efficiency, supplying leukemia cells with an energetic advantage that bolsters survival and adaptation against targeted therapies like venetoclax. Experimental inhibition of ALKBH1, especially in concert with venetoclax treatment, yielded significant anti-leukemic effects with minimal toxicity in preclinical models, highlighting a promising therapeutic axis that could overcome refractory AML and perhaps other ALKBH1-driven malignancies.

Turning to breast cancer, researchers led by Dr. John Carpten have delivered an unprecedented genomic landscape analysis of triple-negative breast cancer (TNBC) in Black women. This aggressive subtype, characterized by the absence of estrogen, progesterone, and HER2 receptors, disproportionately affects younger African American women with poorer prognosis. By sequencing tumor genomes from over four hundred Black women, the study disclosed distinctive mutational patterns, notably a higher frequency of TP53 mutations and a lower prevalence of PIK3CA mutations compared to other populations. Notably, the tumors segregated into two distinct genomic subtypes with divergent clinical trajectories—one associated with younger age and better survival marked by a robust mutational burden, and another linked to older age, elevated body mass index, attenuated immune responses, and poorer outcomes. These findings not only provide crucial insights into the molecular underpinnings of racial disparities in TNBC but also point towards tailored immunotherapeutic and targeted intervention strategies that could enhance survival in this underserved demographic.

Immunotherapy innovation took a leap forward with research into Th9 cells, a subset of helper T cells endowed with formidable anti-tumor activity. The City of Hope team, including Drs. Michael Caligiuri and Shoubao Ma, dissected the molecular brakes imposed by YTHDF2, an RNA-binding protein that regulates the development and function of Th9 cells. By genetically removing YTHDF2, they unleashed a proliferation of hyperactive Th9 cells exhibiting enhanced tumor-killing capabilities. This revelation opens new avenues for CAR T cell engineering, where reprogrammed Th9 cells can be harnessed to confront solid tumors—long considered impregnable by traditional CAR T therapies. Such enhancements could dramatically expand the reach and potency of cellular immunotherapeutics.

In a striking and unconventional pivot, City of Hope scientists have developed a CAR T cell therapy for glioblastoma that incorporates chlorotoxin, a peptide derived from scorpion venom, to target malignant brain tumors with precision. This innovative approach, pioneered by neurosurgeon Dr. Behnam Badie and colleagues, exploits chlorotoxin’s natural affinity for glioblastoma cell membranes without harming normal brain tissue. Early-phase clinical trials demonstrated safety and tolerability, with CAR T cells persisting in the tumor microenvironment and achieving temporary disease stabilization in most patients despite the aggressive nature of glioblastoma. This pioneering work embodies a fusion of natural toxin biology and synthetic immunotherapy, offering renewed hope against one of the deadliest cancers known.

Further advancing the fight against recalcitrant tumors, City of Hope researchers engineered an oncolytic virus named CF33-hNIS-antiPDL1 designed to infiltrate and dismantle the immunosuppressive microenvironment of pancreatic ductal adenocarcinoma (PDAC). This virus not only selectively infects and lyses pancreatic cancer cells but also expresses a checkpoint inhibitor targeting PD-L1, a protein that tumors exploit to evade immune detection. In preclinical models, this dual-action viral therapy significantly curtailed tumor growth, enhanced immune cell infiltration, and prolonged survival. Notably, intraperitoneal administration of CF33-hNIS-antiPDL1 yielded superior efficacy over systemic delivery, highlighting the importance of delivery routes in virotherapy. These findings propel CF33 derivatives as potent candidates in the quest to breach pancreatic cancer’s formidable immune defenses.

Together, these advances epitomize the sophisticated convergence of molecular biology, genomic medicine, immunoengineering, and virotherapy in contemporary oncology research. City of Hope’s integrated model—from deep mechanistic studies, through translational preclinical evaluation, to pioneering clinical trials—embodies a paradigm shift towards personalized, multi-dimensional cancer care. The elucidation of ALKBH1’s mitochondrial modulation in AML enriches the therapeutic arsenal against drug resistance, while the human genomic insights into TNBC highlight the critical need to address racial disparities with precision medicine. CAR T cell evolutionary leaps through Th9 enhancement and venom-based targeting redefine immunotherapy’s potential against formidable solid tumors. Lastly, the marriage of viral engineering and checkpoint blockade holds promise to transform the grim landscape of pancreatic cancer prognosis.

These breakthroughs, supported by national and international collaborations, including licensing partnerships with biotechnology firms, reaffirm City of Hope’s status as a beacon of innovation in cancer research. Ensuring equitable access to these therapies and continued inclusion of diverse populations in clinical studies remain imperative. As these novel strategies progress from bench to bedside, they embody a collective promise to redefine cancer survivorship and ultimately translate scientific insight into lasting hope for patients worldwide.

Subject of Research: Acute Myeloid Leukemia, Triple-negative Breast Cancer, CAR T Cell Therapy, Glioblastoma, Pancreatic Cancer

Article Title: City of Hope Unveils Molecular and Therapeutic Innovations to Combat Resistant Cancers

News Publication Date: Not specified

Web References:
– https://www.cityofhope.org/
– https://aacrjournals.org/cancerdiscovery/article/10.1158/2159-8290.CD-24-1043/763931/ALKBH1-drives-tumorigenesis-and-drug-resistance
– https://www.nature.com/articles/s41588-025-02322-y
– https://www.nature.com/articles/s41590-025-02235-2
– https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00375-1
– https://www.sciencedirect.com/science/article/pii/S075333222500602X

References:
– Chen, J. et al. ALKBH1 Drives Tumorigenesis and Drug Resistance in AML. Cancer Discovery.
– Carpten, J. et al. Genomic Landscape and Distinct Subtypes of Triple-Negative Breast Cancer in Black Women. Nature Genetics.
– Caligiuri, M., Ma, S. YTHDF2 Regulates Th9 Cell Development and Enhances CAR T Immunotherapy. Nature Immunology.
– Badie, B., Barish, M., Brown, C. CLTX-CAR T Cells for Glioblastoma: Early Clinical Trial Outcomes. Cell Reports Medicine.
– Woo, Y. et al. CF33 Oncolytic Virus Engineered to Block PD-L1 in Pancreatic Cancer. Biomedicine & Pharmacotherapy.

Image Credits: City of Hope

Keywords: Myeloid leukemia, Triple-negative breast cancer, CAR T therapy, Glioblastoma, Pancreatic cancer, ALKBH1, TP53 mutation, YTHDF2, Chlorotoxin, Oncolytic virus, Immune checkpoint blockade, Cancer drug resistance

The concept of using PROTACs (Proteolysis Targeting Chimeras) in cancer treatment has generated immense interest in the scientific community. PROTACs represent a cutting-edge technology that harnesses the body’s ubiquitin-proteasome system to selectively degrade specific proteins implicated in cancer progression. ARV-825, a novel PROTAC, has shown promise in targeting the BET (bromodomain and extraterminal) family of proteins, which play a crucial role in tumor growth and survival. However, one major limitation that has hindered its clinical application is the effective delivery of ARV-825 across the BBB.

Recognizing the limitations of traditional administration routes, the researchers focused on developing a nanosuspension that incorporates permeability enhancers, allowing the therapeutic agent to cross the BBB more efficiently. This groundbreaking formulation leverages advanced nanotechnology to create a nanoscale suspension that increases the drug’s surface area, promoting its absorption in the intestinal tract and subsequent entry into the systemic circulation. By employing biocompatible and biodegradable materials, the researchers ensured that the formulation not only enhances the therapeutic effects of ARV-825 but also minimizes potential toxicity.

In laboratory tests, the oral nanosuspension demonstrated enhanced solubility and stability compared to conventional formulations. The researchers conducted a series of experiments to evaluate the pharmacokinetics of the nanosuspension, which revealed promising results. The oral administration of the formulation led to significantly higher plasma concentrations of ARV-825 compared to its traditional counterparts. These findings suggest that the permeability-enhanced nanosuspension could potentially translate to more robust therapeutic outcomes in glioblastoma patients.

Another critical aspect of this research involves the safety profile of the new formulation. While enhancing drug permeability is essential for efficacy, it is equally crucial to ensure that such modifications do not compromise safety. The team conducted extensive preclinical safety assessments, employing various animal models to evaluate potential adverse effects. Early results indicate that the formulation is well-tolerated, with no significant signs of toxicity observed in the test subjects. This safety assurance lays the groundwork for future clinical trials, where the efficacy and tolerability of the nanosuspension will be assessed in human participants.

The innovative combination of PROTAC technology with advanced nanotechnology has the potential to herald a new era in glioblastoma treatment. By enhancing the delivery of ARV-825, the researchers are targeting the root of the problem: the efficiency of drug delivery to brain tissues. This aspect is particularly crucial given the limited treatment options available for glioblastoma, which often results in poor patient outcomes. The formulation optimistically represents a significant advancement that could not only improve survival rates but also enhance the quality of life for patients struggling with this aggressive cancer.

Furthermore, the approach of combining a PROTAC with a specialized oral delivery system might also inspire research into similar therapies for other types of cancers. As studies continue to reveal more about the molecular underpinnings of various malignancies, the hope is that similar innovations can be adapted to address different therapeutic challenges across oncology.

The findings from Patel, Yadav, and Dukhande also raise exciting prospects for personalized medicine in oncology. As healthcare increasingly moves towards individualized treatment strategies, the ability to enhance drug delivery systems could allow for tailored therapeutic regimens that maximize efficacy based on a patient’s specific tumor characteristics. This personalization may eventually result in more effective and fewer side-effect treatment options, a long-sought goal in the cancer research community.

Collaboration between researchers, pharmaceutical industries, and regulatory bodies will be essential as this research moves toward clinical applications. The transition from bench to bedside is fraught with challenges, yet the significance of this work cannot be overstated. Ensuring sufficient funding, support for advanced manufacturing processes, and adherence to rigorous regulatory standards will facilitate the development of this promising therapeutic strategy.

As public awareness increases around the urgency of brain cancer research, studies like this one shine a light on the critical need for innovative solutions. Engaging with patient advocacy groups and educational initiatives will help disseminate knowledge and foster broader support for promising research endeavors. Such efforts create a conducive environment for innovative scientific exploration, leading to potentially transformative solutions in cancer treatment.

In conclusion, the research conducted by Patel and team makes substantial contributions to the ongoing battle against glioblastoma. The exploration of permeability-enhanced nanosuspension for the oral delivery of ARV-825 PROTAC not only offers hope for improved treatment outcomes but also sets the foundation for potentially groundbreaking developments in cancer therapy. As the scientific community continues to grapple with the complexities of drug delivery and cancer biology, collaborative efforts driving this innovative research could reshape the future of glioblastoma treatment and beyond.

The implications of this study extend beyond glioblastoma, highlighting the versatility of PROTAC technology and advanced delivery systems. By successfully engineering a formulation that addresses the critical challenge of drug delivery, researchers are poised to broaden the scope of PROTAC applications. Ultimately, this work paves the way for a new chapter in the fight against cancer where better-targeted therapies and innovative treatment strategies may become the norm rather than the exception.

The research undertaken by Patel, Yadav, and Dukhande serves as a crucial reminder of the impact that cutting-edge science can have on patient care and treatment modalities. Such innovations can spark hope in patients and their families, showcasing the relentless pursuit of better solutions in the realm of oncology. As clinical trials unfold, the medical community eagerly anticipates the firsthand results of this groundbreaking research.

While the road ahead remains challenging, the potential for improved life-saving therapies in glioblastoma and other malignancies remains rich with possibilities. The increasing integration of nanotechnology with traditional therapeutic approaches may soon bring forth a brighter future for cancer patients worldwide.

Subject of Research: Oral nanosuspension of ARV-825 PROTAC for glioblastoma treatment

Article Title: Permeability enhancer incorporated oral nanosuspension of ARV-825 PROTAC for Glioblastoma treatment.

Article References:

Patel, H., Yadav, A., Dukhande, V. et al. Permeability enhancer incorporated oral nanosuspension of ARV-825 PROTAC for Glioblastoma treatment.
J. Pharm. Investig. (2025). https://doi.org/10.1007/s40005-025-00771-5

Image Credits: AI Generated

DOI: 10.1007/s40005-025-00771-5

Keywords: Glioblastoma, PROTAC, ARV-825, Nanosuspension, Drug delivery

Glioblastoma is notorious for its aggressive nature and poor patient survival, with standard-of-care treatments rarely extending life beyond 14 to 16 months post-diagnosis. The heterogeneity of this malignancy, compounded by molecular subtypes resistant to existing chemotherapy agents, underscores the urgent need for innovative treatment modalities. Recognizing this, the research team embarked on a mission to dissect the molecular underpinnings of glioblastoma’s resilience. They identified the myosin motor proteins—fundamental components that convert chemical energy into mechanical forces within cells—as key facilitators in tumor expansion and resistance mechanisms.

Myosin motors operate within a cellular environment much like miniature machines, orchestrating diverse processes such as motility, shape change, and intracellular transport. Their critical involvement in muscle cells is well-known, but their role in pathological states, including cancer progression, has remained largely unexploited due to the scarcity of selective pharmacological inhibitors. This gap presented both a challenge and an opportunity. By engineering a suite of small-molecule inhibitors capable of selectively incapacitating myosin motors involved in glioblastoma pathology, the team aimed to disrupt the cancer’s cellular machinery at a fundamental level.

The medicinal chemistry efforts, helmed by Dr. Theodore Kamenecka in collaboration with structural biologist Dr. Patrick Griffin, culminated in the synthesis of MT-125, a molecule specifically designed to inhibit non-muscle myosin II (NMII) functions within malignant cells. Early experimental models revealed that MT-125 impedes the contractile forces that cancer cells deploy to invade adjacent brain tissue, effectively "locking" them in place. This biophysical blockade stifles the tumor’s notorious ability to infiltrate and colonize new niches within the brain, which is a primary factor contributing to patient mortality.

A hallmark discovery in the research was MT-125’s ability to convert glioblastoma cells from radiation-resistant phenotypes into radiation-sensitive ones. Treated cells exhibited multinucleation—a condition where cells fail to undergo proper division and become marked for programmed cell death. This mechanistic insight was corroborated through murine models, where MT-125, both as a monotherapy and in combination with the kinase inhibitor sunitinib, elicited dramatic tumor regressions. These findings suggest a synergistic augmentation of existing chemotherapeutic regimens, opening avenues for combinatorial therapies with enhanced potency.

Despite the promising outcomes, the researchers caution against premature extrapolation to human clinical success. The biological divergence between murine models and human patients necessitates cautious optimism, with comprehensive toxicity profiling and dosing strategies integral to future studies. Notably, MT-125 displays preferential toxicity towards cancer cells over healthy tissue and possesses a pharmacokinetic profile suitable for pulsed administration, which may mitigate adverse effects commonly associated with chemotherapy.

The therapeutic significance of targeting molecular motors extends beyond glioblastoma. The science behind MT-125 opens a new frontier where disabling the mechanical underpinnings of malignant cells can be harnessed across a spectrum of cancers, potentially transforming treatment paradigms. Such a strategy veers away from traditional methods that primarily target genetic signals, focusing instead on the biophysical mechanisms essential to tumor progression.

In parallel with their oncology research, the team is advancing a related compound, MT-110, which holds promise in addressing methamphetamine use disorder by modulating myosin motor-driven neuronal pathways associated with drug craving. This illustrates the broad therapeutic potential of myosin motor inhibitors, resonating beyond cancer treatment to neurological and psychiatric diseases.

The pathway to bringing MT-125 from bench to bedside is well underway. The compound has been licensed to Myosin Therapeutics, a biotechnology startup founded by the principal investigators. With FDA approval granting clearance to initiate clinical trials, the team anticipates enrolling glioblastoma patients within the year. Substantial funding from the National Institutes of Health and dedicated glioblastoma research endowments supports this ambitious effort, laying the foundation for translational success.

Clinical trials will critically evaluate safety, dosing regimens, and efficacy in the complex and heterogeneous landscape of human glioblastoma. If successful, MT-125 could herald a new era where intractable brain tumors are rendered vulnerable to existing therapies, dramatically improving patient outcomes that have remained stagnant for decades.

This landmark research embodies the impact of interdisciplinary collaboration—melding medicinal chemistry, structural biology, neuro-oncology, and clinical expertise—to tackle one of the most formidable challenges in cancer treatment. By reimagining glioblastoma therapy through the lens of cellular mechanics, the scientists have illuminated a transformative therapeutic axis poised to advance the future of oncology.

Subject of Research: Animals

Article Title: Scientists wipe out aggressive brain cancer tumors by targeting cellular ‘motors’

News Publication Date: 1-Jul-2025

Web References:

• Research article in Cell: https://www.cell.com/cell/fulltext/S0092-8674(25)00569-0
• DOI link: http://dx.doi.org/10.1016/j.cell.2025.06.006

Image Credits: Image courtesy Steven Rosenfeld, M.D., Ph.D., and Courtney Miller, Ph.D.

Keywords: Glioblastomas, Brain cancer, Cancer